Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2026, with a report date of April 16, 2026. The document serves as a transaction notification detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). These transactions were executed on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS) between April 9 and April 14, 2026.
Key Financial Metrics and Transaction Details
The filing does not contain corporate financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share transactions. Key transaction data includes:
- Instrument Types: Ordinary Shares (ISIN: GB00BN7SWP63) and American Depositary Shares (ADS) (ISIN: US37733W2044).
- Transaction Nature: All reported transactions were increases in notional interest or acquisitions resulting from the re-investment of dividends paid on April 9, 2026, under the Company's Deferred Annual Bonus Plan or pension plans.
- Ordinary Share Price: Transactions on XLON occurred at a uniform price of £21.6700.
- ADS Prices: Transactions on XNYS occurred at prices ranging from $58.3499 to $59.1703.
- Participants: Transactions involved senior executives including the CEO (Luke Miels), CFO (Julie Brown), and various Non-Executive Directors.
Material Changes Versus Prior Period
The filing text does not provide comparative data against prior periods, nor does it report on changes in corporate financial performance, market share, or operational metrics. The document is a statutory disclosure of specific insider trading events and does not contain historical trend analysis.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The only descriptive text provided is a standard company overview stating GSK is a global biopharma company focused on uniting science, technology, and talent.
Important Facts for Investor Verification
- Verify the dividend payment date of April 9, 2026, to confirm the timing of the re-investment transactions.
- Confirm the share price of £21.6700 on the London Stock Exchange for April 14, 2026, to validate the transaction values.
- Note that all reported transactions were non-discretionary dividend re-investments, not open-market purchases or sales.
- Check the specific volumes for each executive to understand the scale of their notional interest increases (e.g., CEO Luke Miels acquired 1,178 Ordinary Shares).
- Recognize that this filing provides no insight into GSK's overall financial health or operational results for the period.